Zühlke worked with Breathonix to set solid foundations for their solution architecture and identify opportunities through advanced technologies to scale their digital and innovation capabilities.
- Breathonix’s BreFence™ Go is the first COVID-19 system to receive provisional authorisation from Singapore’s Health Sciences Authority (HSA)
- Zühlke supported Breathonix as a strategic partner in their innovation and data-driven deployment efforts
- Zühlke brought multidisciplinary expertise to ensure that their solution is future-proof and embed important considerations like data security into their product roadmap
As the world reopens to the new normal, many countries are coping with the strategy of living with COVID-19 where testing becomes a “way of life”. To facilitate testing for the mass public, a solution that offers speed, affordability, and accuracy is significantly improving the screening process.
Developed by Singapore-based start-up Breathonix, BreFence™ Go is the first COVID-19 breath test system to receive provisional authorisation from Singapore’s Health Sciences Authority (HSA) in May 2021. The breath analysis system generates test results within a minute — a fraction of the time needed for a polymerase chain reaction (PCR) test, the current gold standard for testing.
Zühlke supported Breathonix as a strategic technology partner in their digital innovation and data-driven deployment efforts as they scale up.
A solution that accelerates accurate, affordable mass screening
Delivering results in less than a minute, Breathonix’s BreFence™ Go solution uses a proprietary software algorithm to analyse VOCs biomarkers, achieving a 90% accuracy through past clinical trials. The breath testing system does not require trained healthcare personnel or laboratory processing and costs significantly lesser than the widely used PCR test, thereby reducing manpower and resources required for mass screening.
MyEG, a Malaysia government service provider, and Vingroup, a local conglomerate in Vietnam, has announced partnerships with Breathonix to bring in the BreFence™ Go COVID-19 breath testing system as part of their contribution towards the global fight against COVID-19, demonstrating demand and market potential for such mass testing diagnostic technology.
“Here at Breathonix, we aim to disrupt the billion-dollar diagnostic industry with affordable, accurate, and non-invasive solutions for disease detection. With Zühlke, we found a partner with long-standing technical expertise in the Healthcare industry, supporting us with practical insights and guidance on how we approach technical infrastructure and data governance for scaling our solutions for the next phase of growth,” said Wayne Wee, Head of Strategy & Business Development at Breathonix.
The challenge: Build, deliver and scale fast
For many innovative start-ups like Breathonix who are looking to transform the health industry, the biggest challenges remain on speed to market and infrastructure scalability that supports high-performing secured computing to handle highly regulated patient’s data.
“Being agile and having the ability to scale their digital and innovation capabilities is critical for many start-ups like Breathonix, especially at their state of growth. At Zühlke, we’re excited to support rising innovators to help them address ever-changing demands and improve resilience across their core operations through technology and best practices from the field. Together, we worked with Breathonix to set solid foundations for their solution architecture and identify opportunities through advanced technologies,” said Kiky Shannon, BD Enterprise & Public Sector at Zühlke.
With support from Zühlke, Breathonix’s engineering teams worked closely with multidisciplinary experts to navigate the unknown, ensuring that their solution is future-proof and embedding important considerations like data security into their product roadmap.
Partnering with Zühlke early in their product scaling phase, Breathonix achieved a clearer vision for the technical architecture to make the right technological decisions and investments to support their future data capabilities.
“With innovation capabilities like data and AI taking off to drive new discoveries in ways to provide improved patient care, organisations will need to bring in new talent and strengthen ecosystem collaborations to meet market needs. The healthcare sector is one of the most important domains that impact the global population and remains a key expertise area for Zühlke. We look forward to continuing supporting next-generation innovators like Breathonix in their digital innovation breakthroughs to improve treatments and outcomes for a better, smarter future for healthcare,” said Jonas Trindler, CEO Asia & Partner of Zühlke Group.